NeutralMEDIUM severityHealthcare & Pharma7d ago

Premarket movers: Sanmina, AAON surge; Hims & Hers, Rocket Lab fall

Premarket movers: Sanmina, AAON surge; Hims & Hers, Rocket Lab fall — $HIMS one-month chart
$HIMS daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about HIMS. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · Hims & Hers HealthEvent risk Moderate
  • Key person: Filed with SEC
  • Clear: legal, regulatory, security, operational, financial integrity
From here · options-implied volatility 72% a year
Now $17.75Week $15.94–$19.55 (±10.2%)Month $14.05–$21.44 (±20.8%)

Options price an average move of ±17.6% by Dec 18 — the at-the-money straddle, the typical size of the move; the bands are one standard deviation.

Early signals (1) — filed with the SEC or first reported, not yet widely covered
  • Key person · SEC 8-K, Item 5.02, Nov 9: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Ask Wook AI

Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.

Wook analysis

What it means

Key points
  • What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
  • How the stock is trading: $HIMS -4.53% in the latest session.
  • Timing: It came out pre-market, so the next session was the first that could react.

Where the stock stands

Hims & Hers Health ($HIMS) fell 4.53% to $17.72 in the latest session. Over the past month it is down 37.0%. That leaves it 57% below its 52-week high of $40.99 and 29% above its low of $13.74. The year's high was 3.0 times its low, which makes double-digit swings fairly routine here.

What the filings say

In its latest report (10-Q, filed Nov 9, 2026), $HIMS lost $33.0M over the quarter to Sep 30, 2026 on revenue of $890.4M (+18.2% QoQ). Operations brought in $118.8M of cash over the nine months to Sep 30, 2026. Total liabilities were $3.19B against $605.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 9, 1 day before this story; it is $HIMS's own account and the first thing to read. Figures are as filed with the SEC; the $HIMS page has the full statements.

How much coverage it is getting

Wook has filed 7 stories on Hims & Hers Health in the last 30 days, 1 of them this week. Its 30-day average is about 2 a week, so this week is quieter than usual. Going by their wording, 3 read bullish, 3 neutral and 1 bearish. This one reads neutral, along with a sizeable minority of them. 3 came from Investing.com and the rest from other outlets, so more than one newsroom is on it.

The bigger picture

Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.

What to watch next

The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $HIMS page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $HIMS: its distance from the high, its last report, or how coverage has changed.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Investing.com published this on November 10, 2026. $HIMS has moved -21.77% ($22.65 to $17.72). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Investing.com. Wook of Wall Street is an independent research tool and is not affiliated with Investing.com. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy